Get the Stockscreener App
9.52
22.73%
-2.80
After Hours:
9.53
0.010
+0.11%
Intellia Therapeutics Inc stock is traded at $9.52, with a volume of 25.34M.
It is down -22.73% in the last 24 hours and down -53.42% over the past month.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
See More
Previous Close:
$12.32
Open:
$9.145
24h Volume:
25.34M
Relative Volume:
3.40
Market Cap:
$1.02B
Revenue:
$52.86M
Net Income/Loss:
$-480.19M
P/E Ratio:
-2.0299
EPS:
-4.6899
Net Cash Flow:
$-421.82M
1W Performance:
-24.56%
1M Performance:
-53.42%
6M Performance:
+30.59%
1Y Performance:
-40.50%
1-Day Range:
$8.96
$10.11
1-Week Range:
$8.96
$13.69
52-Week Range:
$5.90
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Name
Intellia Therapeutics Inc
Sector
Industry
Phone
857-285-6200
Address
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
9.52 | 1.32B | 52.86M | -480.19M | -421.82M | -4.6899 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-28-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-28-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-27-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-27-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-06-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Apr-21-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-05-25 | Initiated | H.C. Wainwright | Buy |
| Feb-28-25 | Downgrade | Goldman | Neutral → Sell |
| Feb-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-27-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-23-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Apr-13-23 | Initiated | Canaccord Genuity | Buy |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Mar-14-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-24-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-19-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Sell |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Jun-16-22 | Initiated | BofA Securities | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Feb-18-22 | Initiated | William Blair | Outperform |
| Feb-07-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-22 | Initiated | Cowen | Outperform |
| Jan-07-22 | Initiated | Piper Sandler | Overweight |
| Oct-05-21 | Initiated | Guggenheim | Buy |
| Sep-24-21 | Initiated | Stifel | Buy |
| Jun-28-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-11-21 | Initiated | H.C. Wainwright | Buy |
| May-07-21 | Upgrade | ROTH Capital | Neutral → Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
| Dec-22-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-27-20 | Initiated | Truist | Buy |
| Oct-14-20 | Initiated | Wells Fargo | Overweight |
| Sep-18-20 | Initiated | Goldman | Buy |
| Feb-28-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-14-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-01-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-09-19 | Initiated | Robert W. Baird | Outperform |
| Jun-10-19 | Initiated | ROTH Capital | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Nov-02-18 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-29-18 | Initiated | Credit Suisse | Neutral |
| Sep-21-18 | Initiated | Raymond James | Mkt Perform |
| May-15-18 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-08-18 | Initiated | JMP Securities | Mkt Outperform |
| Nov-01-17 | Reiterated | Jefferies | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
| Aug-05-16 | Upgrade | Jefferies | Hold → Buy |
View All
Intellia Therapeutics Inc Stock (NTLA) Latest News
Patient Treated in Trial for Intellia’s Transthyretin Amyloidosis Gene Editing Therapy Nex-Z Dies - CGTLive®
Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran in Patients with Hereditary Angioedema - Investing News Network
Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema - Intellia Therapeutics
Intellia Therapeutics (NASDAQ: NTLA) reports 89% kallikrein reduction at 24 months in HAE - Stock Titan
Intellia Therapeutics Faces Woes as Price Targets Slashed Amid Safety Concerns - StocksToTrade
Is Intellia Therapeutics Inc. still worth holding after the dipWeekly Trend Recap & Consistent Profit Alerts - newser.com
Chardan Capital Maintains Intellia Therapeutics (NTLA) Buy Recommendation - Nasdaq
Can volume confirm reversal in Intellia Therapeutics Inc.Analyst Upgrade & Proven Capital Preservation Tips - newser.com
Intellia Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks
Citizens Maintains Intellia Therapeutics (NTLA) Market Outperform Recommendation - Nasdaq
Wells Fargo Maintains Intellia Therapeutics (NTLA) Equal-Weight Recommendation - Nasdaq
NTLA: Analyst Chardan Capital Lowers Price Target; Maintains Buy Rating | NTLA Stock News - GuruFocus
How Intellia Therapeutics Inc. (NTLA) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Wells Fargo Lowers PT on Intellia Therapeutics (NTLA), Maintains Rating | NTLA Stock News - GuruFocus
NTLA: RBC Capital Maintains Rating, Lowers Price Target by 36% | - GuruFocus
Intellia Therapeutics patient death prompts FDA clinical hold on CRISPR heart disease trials - The Business Journals
RBC Adjusts Price Target on Intellia Therapeutics to $9 From $14, Maintains Sector Perform Rating - MarketScreener
Patient Dies After Treatment with Intellia CRISPR Therapy in Phase III Trial - Genetic Engineering and Biotechnology News
Patient dies in Intellia trial; FDA awards 6 more ‘national priority’ vouchers - BioPharma Dive
Intellia Therapeutics reports Q3 EPS (92c) vs. ($1.34) last year - TipRanks
Intellia Therapeutics Says a Patient Died in Gene Editing Trial - Barron's
Wedbush Maintains NTLA Rating, Lowers Price Target to $7 | NTLA Stock News - GuruFocus
NTLA’s Trials Pause: A Trigger for Stock Decline? - StocksToTrade
Intellia Tumbles After Patient Dies Following Crispr Treatment - Bloomberg.com
Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble - TradingView
Intellia Therapeutics stock price target lowered to $9 at RBC after patient death - Investing.com Canada
NTLA's Analyst Rating Maintained but Price Target Lowered | NTLA Stock News - GuruFocus
Patient with liver damage in Intellia trial dies - statnews.com
Intellia Therapeutics’ stock rocked by patient death in gene therapy trial - Clinical Trials Arena
Intellia Therapeutics (NTLA) Reports Strong Revenue Growth and S - GuruFocus
Is It Too Late to Buy NTLA? - timothysykes.com
2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street - AOL.com
Intellia Therapeutics Stock (NTLA) Opinions on Clinical Trial Suspension - Quiver Quantitative
Intellia shares fall after hospitalised CRISPR patient dies - Pharmaphorum
Patient Dies After Receiving Intellia’s CRISPR Gene Therapy Candidate - BioSpace
Intellia Therapeutics (NTLA) Shares Plunge After Phase 3 Trial S - GuruFocus
JPMorgan Downgrades Intellia Therapeutics to Underweight From Neutral, Adjusts Price Target to $5 From $12 - MarketScreener
JP Morgan Downgrades Intellia Therapeutics (NTLA) with Lower Pri - GuruFocus
Intellia stock plunges after patient death (NTLA:NASDAQ) - Seeking Alpha
Chart overlay techniques for tracking Intellia Therapeutics Inc.Forecast Cut & High Win Rate Trade Alerts - newser.com
Patient hospitalised after receiving Intellia's CRISPR therapy dies - FirstWord Pharma
Intellia Therapeutics (NTLA) Faces Setback with FDA Hold on Key Trials - GuruFocus
Intellia Therapeutics stock rating maintained at Neutral by Baird - Investing.com India
Cautious Hold Rating on Intellia Therapeutics Amid Safety Concerns and Regulatory Uncertainty - TipRanks
Intellia Therapeutics downgraded to Underweight from Neutral at JPMorgan - TipRanks
Transcript : Intellia Therapeutics, Inc., Q3 2025 Earnings Call, Nov 06, 2025 - MarketScreener
Patient dies after receiving Intellia's CRISPR therapy - Fierce Biotech
JPMorgan downgrades Intellia Therapeutics stock on liver toxicity concerns - Investing.com
How sentiment analysis helps forecast Intellia Therapeutics Inc.Quarterly Earnings Summary & Precise Buy Zone Identification - newser.com
Intellia Trims Losses And Edges Toward Major Drug Launch - Finimize
Patient in Intellia CRISPR trial dies after being hospitalized with liver injury - Endpoints News
Intellia Therapeutics Inc Stock (NTLA) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.44%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):